샘플 요청 목록

 카트 문의
시장보고서
상품코드
1771612

FISH 프로브 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 유형별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Fluorescent In Situ Hybridization Probe Market Size, Share & Trends Analysis Report By Technology (Flow FISH, Q FISH), By Type (DNA, RNA), By Application, By End-use (Research, Clinical use), By Region, And Segment Forecasts, 2025 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

FISH 프로브 시장 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 FISH 프로브 시장 규모는 2025년부터 2030년까지 연평균 복합 성장률(CAGR) 7.78%를 나타내며, 2030년에는 14억 8,588만 달러에 달할 것으로 예측됩니다.

암 등의 대상 질환에 걸리기 쉬운 세계 인구 증가는 정확하고 효과적인 진단에 대한 수요 증가로 이어지고 있습니다. 예를 들어, 미국 암 협회 암 통계 2023에 따르면 2023년에 미국에서 약 190만 건의 새로운 암이 진단될 것으로 예상됩니다.

또한 ICMR의 2021년 보고서에 따르면 세계의 인도의 암 환자수는 2021년 2,670만명에서 2025년에는 2,980만명으로 증가할 것으로 예측되고 있습니다. FISH 기술은 특정 DNA 서열의 정확한 국소화, 유전병 진단, 유전자 매핑, 다양한 유형의 암과 관련된 새로운 암 유전자의 동정 등 다양한 목적에 유용합니다.

또한, 장기간에 걸친 연구를 위한 분석 샘플의 보존 시간 연장과 같은 CISH의 기술적 진보는 향후 몇 년 동안 네비게이션 시스템 수요를 촉진할 것으로 예측됩니다. FISH는 엔젤만 증후군, 프라더-윌리 증후군, 만성 골수성 백혈병, 다운 증후군, 심혈관 안면 증후군, 22q13 결실 증후군, 급성 림프모구 백혈병(ALL), 크리-두-챗과 같은 유전 질환의 검출에 가장 일반적으로 사용되며, 유전 질환의 진단을 위해 사용됩니다.

이 질병의 유병률이 상승하고 있기 때문에 이러한 유전성 질환을 검출하기 위한 효율적인 진단법을 제공할 필요성이 높아지고 있으며, 나아가 시장 전체의 성장을 견인하고 있습니다. 세계의 발자취를 확대하고 시장에서의 경쟁력을 유지하기 위해 제품 출시, 제휴·협력, M&A 등 다양한 전략을 추진하고 있습니다. 예를 들어, 2023년 3월 OGT(시스멕스 그룹)는 CytoCell FISH 프로브에 대한 IVDR 인증을 받았습니다. 이 회사는 IVDR 인증을 획득한 최초의 FISH 프로브 제조업체로 현저하게 엄격한 규제 기준을 충족하기 위한 흔들림 없는 헌신을 보여주고 있습니다.

FISH 프로브 시장 보고서 하이라이트

  • FLOW-FISH는 2024년에 FISH 프로브 업계에서 35.81%의 최대 점유율을 차지했고 예측 기간 중 가장 성장이 빠른 부문이 되는 것으로 보고되었습니다.
  • DNA 프로브는 특정 유전자 서열, 염색체 이상, 구조적 재배열을 검출하는데 있어서 중요한 역할을 하기 때문에 시장의 최대 부문을 차지하고, 매출 점유율의 55.85%를 차지합니다.
  • 암 진단이 시장의 최대 부문이며, 2024년의 매출 점유율은 43.85%였습니다.
  • 임상 용도는 시장의 최대 부문을 차지하고 2024년의 매출액 점유율은 41.33%였습니다.
  • 북미는 FISH 프로브 시장을 독점해, 2024년에는 44.33%의 점유율을 차지했습니다.
  • 아시아태평양은 FISH 프로브 시장에서 CAGR 9.5%를 나타내 급속히 상승하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 FISH 프로브 시장 변수, 동향, 범위

  • 시장 계통 전망
    • 상위 시장 전망
    • 관련/보조 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • FISH 프로브 시장 분석 툴
    • 업계 분석 - Porter's Five Forces 분석
    • PESTEL 분석

제4장 FISH 프로브 시장 : 기술 추정·동향 분석

  • 기술별 시장 점유율(2024년 및 2033년)
  • 부문 대시보드
  • 세계의 FISH 프로브 시장 : 기술별 전망
  • 시장 규모와 예측 및 동향 분석(2018-2030년)
    • Q FISH
    • 플로우 FISH
    • 기타

제5장 FISH 프로브 시장 : 유형 추정·동향 분석

  • 유형별 시장 점유율(2024년 및 2033년)
  • 부문 대시보드
  • 세계의 FISH 프로브 시장 : 유형별 전망
  • 시장 규모와 예측 및 동향 분석(2018-2030년)
    • DNA
    • RNA
    • mRNA
    • miRNA
    • 기타

제6장 FISH 프로브 시장 : 용도 추정·동향 분석

  • 용도별 시장 점유율(2024년 및 2030년)
  • 부문 대시보드
  • 세계의 FISH 프로브 시장 : 용도별 전망
  • 시장 규모와 예측 및 동향 분석(2018-2030년)
    • 암 진단

제7장 FISH 프로브 시장 : 최종 용도 추정·동향 분석

  • 최종 용도별 시장 점유율(2024년 및 2030년)
  • 부문 대시보드
  • 세계의 FISH 프로브 시장 : 최종 용도별 전망
  • 시장 규모와 예측 및 동향 분석(2018-2030년)
    • 연구
    • 임상 사용
    • 동반진단

제8장 FISH 프로브 시장 : 지역 추정·동향 분석

  • 지역별 시장 점유율 분석(2024년 및 2030년)
  • 지역별 시장 대시보드
  • 세계의 지역 시장 현황
  • 시장 규모, 예측, 동향 분석(2018-2030년)
  • 북미
    • 북미 : SWOT 분석
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 유럽 : SWOT 분석
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 노르웨이
    • 스웨덴
    • 덴마크
  • 아시아태평양
    • 아시아태평양 : SWOT 분석
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 라틴아메리카 : SWOT 분석
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • MEA : SWOT 분석
    • 남아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 쿠웨이트

제9장 경쟁 구도

  • 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
  • 기업/경쟁의 분류
  • 벤더 상황
    • 주요 리셀러 및 채널 파트너 목록
    • Key customers
    • Key company market share analysis, 2024
    • Thermo Fisher Scientific, Inc.
    • PerkinElmer Inc.
    • BioDot
    • Horizon Diagnostics
    • Agilent Technologies, Inc..
    • Abnova Corporation
    • LGC Biosearch Technologies
    • Genemed Biotechnologies, Inc.
    • Oxford Gene Technology IP Limited
    • Biocare Medical, LLC.
    • QIAGEN(Exiqon A/S)
    • GSP Research Institute, Inc.
KTH

Fluorescent In Situ Hybridization Probe Market Growth & Trends:

The global fluorescent in situ hybridization probe market size is expected to reach USD 1,485.88 million by 2030, registering a CAGR of 7.78% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing global population being prone to target diseases, such as cancer, leads to the rising demand for accurate and effective diagnostics. This is expected to boost the market growth. For instance, according to the American Cancer Society Cancer Statistics 2023, it was estimated that approximately 1.9 million new cancer cases will be diagnosed in the U.S. in 2023. The Australian Institute of Health and Welfare (AIHW) 2021 report indicates that there were an estimated 150,782 new cancer cases in Australia in 2021.

Furthermore, the ICMR 2021 Report suggests that the number of cancer patients in India is projected to increase from 26.7 million in 2021 to 29.8 million in 2025. The fluorescent in situ hybridization (FISH) technique serves various purposes, including the precise localization of specific DNA sequences, genetic disease diagnosis, gene mapping, and identification of new oncogenes associated with different types of cancers. The growing investment in cancer genomics is expected to drive the adoption and significance of FISH. In addition, supportive government initiatives, rising healthcare expenditure levels, and increasing awareness pertaining to the benefits associated with this technique are expected to fuel industry growth during the forecast period.

Furthermore, technological advancement in chromogenic in situ hybridization (CISH), such as higher storage time of analyzed samples for long-duration studies, is expected to fuel the demand for navigation systems in the coming years. FISH is most commonly used in the detection of genetic diseases, such as Angelman syndrome, Prader-Willi syndrome, chronic myelogenous leukemia, Down's syndrome, Velocardiofacial syndrome, 22q13 deletion syndrome, acute lymphoblastic leukemia (ALL), and cri-du-chat. According to a publication from the CDC in 2022, Down's syndrome is the most common genetic disorder, with almost one in every 700 newborns affected by the disorder.

The rising prevalence of the condition drives the need to provide efficient diagnostics for detecting these genetic diseases, which, in turn, drives the overall market growth. Furthermore, key participants are engaged in various strategies, such as product launches, partnerships & collaborations, and M&As, to expand their global footprint and maintain competitive position in the market. For instance, in March 2023, OGT (Sysmex Group) received IVDR certification for CytoCell FISH probes. The company is the first manufacturer of FISH probes to receive IVDR certification, showcasing its unwavering commitment to meeting the significantly more rigorous regulatory standards. This certification validates their products' enduring safety, dependability, and efficacy.

Fluorescent In Situ Hybridization Probe Market Report Highlights:

  • FLOW-FISH held the largest share of 35.81% of the fluorescent in situ hybridization probe industry in 2024 and is reported to be the fastest segment over the forecast period.
  • DNA probes represent the largest segment of the market, accounting for 55.85% of revenue share, owing to their critical role in detecting specific gene sequences, chromosomal abnormalities, and structural rearrangements.
  • Cancer diagnostics is the largest segment of the market, with a revenue share of 43.85% in 2024, driven by the technique's ability to detect high precision gene rearrangements, amplifications, and deletions.
  • Clinical use represents the largest segment of the market, accounting for 41.33% in 2024, driven by its widespread application in diagnosing genetic disorders, cancers, and infectious diseases.
  • North America dominated the fluorescent in situ hybridization probe market and accounted for a 44.33% share in 2024, driven by the high adoption of molecular diagnostics and the strong presence of key market players.
  • Asia-Pacific is rapidly emerging with a CAGR of 9.5% in the FISH probe market, driven by rising awareness of genetic diseases and increasing cancer prevalence.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Type
    • 1.2.3. Application
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technology Outlook
    • 2.2.2. Application Outlook
    • 2.2.3. Type Outlook
    • 2.2.4. End Use Outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Fluorescent In Situ Hybridization Probe Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Fluorescent In Situ Hybridization Probe Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Fluorescent In Situ Hybridization Probe Market: Technology Estimates & Trend Analysis

  • 4.1. Technology Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Fluorescent In Situ Hybridization Probe Market by Technology Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Q FISH
      • 4.4.1.1. Q FISH market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. FLOW FISH
      • 4.4.2.1. FLOW FISH market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Others
      • 4.4.3.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Fluorescent in situ Hybridization Probe Market: Type Estimates & Trend Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Fluorescent In Situ Hybridization Probe Market by Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. DNA
      • 5.4.1.1. DNA market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. RNA
      • 5.4.2.1. RNA market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. mRNA
      • 5.4.3.1. mRNA market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. miRNA
      • 5.4.4.1. miRNA market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Other
      • 5.4.5.1. Other market estimates and forecasts 2018 to 2030 (USD Million

Chapter 6. Fluorescent In Situ Hybridization Probe Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Fluorescent In Situ Hybridization Probe Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Cancer Diagnostics
      • 6.4.1.1. Cancer Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.2. Lung
        • 6.4.1.2.1. Lung market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3. Breast
        • 6.4.1.3.1. Breast market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.4. Bladder
        • 6.4.1.4.1. Bladder market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.5. Hematological
        • 6.4.1.5.1. Hematological market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.6. Gastric
        • 6.4.1.6.1. Gastric market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.7. Prostrate
        • 6.4.1.7.1. Prostrate market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.8. Cervical
        • 6.4.1.8.1. Cervical market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.9. Other
        • 6.4.1.9.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.10. Genetic diseases
        • 6.4.1.10.1. Genetic diseases market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.11. Other
        • 6.4.1.11.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Fluorescent in situ Hybridization Probe Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2024 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Fluorescent In Situ Hybridization Probe Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Research
      • 7.4.1.1. Research market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Clinical use
      • 7.4.2.1. Clinical use market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Companion diagnostics
      • 7.4.3.1. Companion diagnostics market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Fluorescent In Situ Hybridization Probe Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. North America: SWOT Analysis
    • 8.5.2. U.S.
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Canada
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. Europe: SWOT Analysis
    • 8.6.2. UK
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. Germany
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. France
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Italy
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Spain
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Norway
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Sweden
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.9. Denmark
      • 8.6.9.1. Key country dynamics
      • 8.6.9.2. Regulatory framework
      • 8.6.9.3. Competitive scenario
      • 8.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Asia Pacific: SWOT Analysis
    • 8.7.2. Japan
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. China
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. India
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. Australia
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. South Korea
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.7. Thailand
      • 8.7.7.1. Key country dynamics
      • 8.7.7.2. Regulatory framework
      • 8.7.7.3. Competitive scenario
      • 8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Latin America: SWOT Analysis
    • 8.8.2. Brazil
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. MEA: SWOT Analysis
    • 8.9.2. South Africa
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. Saudi Arabia
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. UAE
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.5. Kuwait
      • 8.9.5.1. Key country dynamics
      • 8.9.5.2. Regulatory framework
      • 8.9.5.3. Competitive scenario
      • 8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2024
    • 9.3.4. Thermo Fisher Scientific, Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. PerkinElmer Inc.
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. BioDot
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Horizon Diagnostics
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Agilent Technologies, Inc..
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Abnova Corporation
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. LGC Biosearch Technologies
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Genemed Biotechnologies, Inc.
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Oxford Gene Technology IP Limited
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Biocare Medical, LLC.
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. QIAGEN (Exiqon A/S)
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Product benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. GSP Research Institute, Inc.
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Product benchmarking
      • 9.3.15.4. Strategic initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제